Skip to content

Diagnosis of Peripheral Lung Nodules Using Cryobiopsy

Bronchoscopic Diagnosis of Peripheral Lung Nodules Using Endobronchial Ultrasound Guided Forceps and Cryobiopsy. A Randomized-controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04885595
Acronym
Cryo-Nodule
Enrollment
54
Registered
2021-05-13
Start date
2021-04-01
Completion date
2023-05-30
Last updated
2024-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung; Node

Keywords

Cryobiopsy

Brief summary

Since the traditional radial endobronchial ultrasound guided biopsy technique of solitary pulmonary nodules using the forceps has several shortcomings, the purpose of this study is to investigate a new biopsy technique using the transbronchial cryobrobe

Detailed description

This is a prospective randomized trial to assess diagnostic accuracy and safety of cryobiopsy using two different outer diameters. Included patients are 1:1 randomized to receive forceps biopsy following cryobiopsy with a 1.1mm or 1.7mm cryoprobe.

Interventions

PROCEDUREForceps biopsy and cryobiopsy

Once the nodule is visualized by radial EBUS, the position of the probe in relation to the lesion is noted. Routinely, forceps biopsy and cryobiopsy are used serially in each patient within the same session.

Sponsors

University of Zurich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Solitary pulmonary nodule with indication of bronchoscopic diagnostic approach * Age between 18 and 90 years * Written informed consent after participant's information

Exclusion criteria

* Age \< 18 and \> 90 years * Lacking ability to form an informed consent (including impaired judgement, communi-cation barriers) * Contraindication against bronchoscopy (e.g. co-morbidities) * INR \> 2 or Thrombocytes \< 50000 * Double antiplatelet drugs (e.g. ASS and Clopidogrel) within 7 days before biopsy * Anticoagulation with NOAK within 48 hours before biopsy * Moderate or severe pulmonary hypertension (mPAP \> 30 mmHg, RV/RA \>30 mmHg) * Tumors suspicious of endobronchial growth

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic yieldup to 1 monthThe diagnostic yield of the malign lesions that we were able to visualise with EBUS in percentage

Secondary

MeasureTime frameDescription
Size of malign tissue in millimeterup to 1 monthThe biopsies are assessed for size of malign tissue in milimeter
Occurrence of bleeding eventsup to 1 monthOccurrence of bleeding events
Size of harvested tissue in millimeterup to 1 monthThe biopsies are assessed for total size in millimeter
Radial endobronchial utrasound probe orientation (excentric, concentric, adjacent)1 dayLesion orientation with regards of the radial endobronchial ultrasound probe
Occurence of pneumothoraxup to 1 monthDetection with X-ray
Size of artifact-free alvoelar space in percentageup to 1 monthSize of artifact-free alvoelar space in percentage

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026